Sugi Predict

Sugi Predict / Compounds / SCHEMBL3114492

SCHEMBL3114492

SCHEMBL3114492

NC(N)=NC(=O)/C=C/c1ccc(Cl)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PYGL P06737 11/20 0.53
▸ HTR2B P41595 1/20 0.51
▸ NPFFR2 Q9Y5X5 2/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ GUSB P08236 1/20 0.48
▸ NPC1 O15118 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ PTGS2 P35354 1/20 0.47
▸ MAPT P10636 1/20 0.46
▸ CYP1A1 P04798 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP1B1 Q16678 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5425527 0.81 CYP1A2 (0.58) HTR2BKMT2ANPSR1NPC1RAB9A
SCHEMBL5380481 0.81 PYGL (0.60) PYGLGUSBNPC1RAB9ATDP1
SCHEMBL5380483 0.81 PYGL (0.60) PYGLGUSBNPC1RAB9ATDP1
Hydrochloric Acid SCHEMBL5886161 0.80 PYGL (0.58) PYGLNPFFR2GUSBNPC1RAB9A
SCHEMBL5432854 0.79 CYP1A2 (0.63) HTR2BKMT2ANPSR1NPC1RAB9A
SCHEMBL5433146 0.77 HTR2B (0.54) HTR2BPTGS2CYP1A1CYP1A2CYP1B1
SCHEMBL5670837 0.76 HTR2B (0.56) HTR2BKMT2ANPC1RAB9ACYP1A1
SCHEMBL5432585 0.76 TYR (0.57) HTR2BKMT2ARAB9APTGS2MAPT
SCHEMBL7828903 0.75 PYGL (0.62) PYGLKMT2AGUSBNPC1RAB9A
SCHEMBL1124517 0.75 PYGL (0.62) PYGLKMT2AGUSBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP claimed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US claimed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US claimed
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2015-11-05 — — US claimed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US claimed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US claimed
EP-1646371-A2 ANTIVIRAL COMPOUNDS AND METHODS Biotron Limited (AU) 2006-04-19 — — EP claimed
WO-2004112687-A2 ANTIVIRAL ACYLGUANIDINE COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2004-12-29 — — WO claimed
EP-2617709-B1 Guanidine derivatives as antiviral agents BIOTRON LTD (AU) 2022-11-16 — — EP disclosed
US-11192863-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2021-12-07 — — US disclosed
US-10683263-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2020-06-16 — — US disclosed
US-10472332-B2 Antiviral compounds and methods BIOTRON LIMITED (AU) 2019-11-12 — — US disclosed
EP-2826770-B1 ACYLGUANIDINE COMPOUNDS WITH ANTIVIRAL ACTIVITY BIOTRON LTD (AU) 2018-09-12 — — EP disclosed
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS BIOTRON LIMITED (AU) 2017-09-14 — — US disclosed
EP-2617709-A1 Guanidine derivatives as antiviral agents Biotron Limited (AU) 2013-07-24 — — EP disclosed
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS GAGE PETER WILLIAM (AU) 2013-02-07 — — US disclosed
CN-101111475-B Antiviral compounds and methods BIOTRON LTD 2012-09-05 — — CN disclosed
US-20100254942-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS BIOTRON LIMITED (AU) 2010-10-07 — — US disclosed
US-20090099239-A1 Antiviral Compounds and Methods BIOTRON LIMITED (AU) 2009-04-16 — — US disclosed
US-20070099968-A1 Antiviral compounds and methods BIOTRON LIMITED (AU) 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100254942-A1 HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS HAVCR2, HCCS, EIF2AK2 PYGL 11/4885HTR2B 4715/4885NPFFR2 4583/4885
US-11192863-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 PYGL 2666/4885HTR2B 4140/4885NPFFR2 4657/4885
US-10683263-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 PYGL 1426/4885HTR2B 4534/4885NPFFR2 4096/4885
US-10472332-B2 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 PYGL 2666/4885HTR2B 4140/4885NPFFR2 4657/4885
US-20070099968-A1 Antiviral compounds and methods MAVS, ZC3HAV1, EIF2AK2 PYGL 2390/4885HTR2B 4329/4885NPFFR2 4775/4885
US-20170260147-A1 ANTIVIRAL COMPOUNDS AND METHODS MAVS, ZC3HAV1, EIF2AK2 PYGL 2666/4885HTR2B 4140/4885NPFFR2 4657/4885
US-20090099239-A1 Antiviral Compounds and Methods MAVS, ZC3HAV1, EIF2AK2 PYGL 1426/4885HTR2B 4534/4885NPFFR2 4096/4885
US-20130035328-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 PYGL 2568/4885HTR2B 4247/4885NPFFR2 4705/4885
US-20150313909-A1 ANTIVIRAL COMPOUNDS AND METHODS ZC3HAV1, MAVS, EIF2AK2 PYGL 2568/4885HTR2B 4247/4885NPFFR2 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback